Abstract 7P
Background
Clear cell renal cell carcinoma (ccRCC), accounting for 80% of renal cell carcinoma (RCC) cases, is a common and deadly urological cancer. Only a small proportion of ccRCC patients obtain durable benefits from immunotherapy. Therefore, exploring novel predictive biomarkers for immunotherapy would be beneficial in guiding personalized clinical management for ccRCC patients.
Methods
The mass spectrum (MS) analyzation, co-immunoprecipitation (Co-IP), immunocytochemistry (ICC) are conducted to identify and confirm the interaction of ACOX2 and MRE11. The protein markers are detected by western blot (WB) and ICC to evaluate the effects of ACOX2 on homologous recombination repair (HRR) and double-strand break (DSB). Picogreen dyeing, WB, ELISA, and immunohistochemistry (IHC) are applied to test the role of ACOX2 in cGAS-STING pathway. Multiple immunohistochemistry (mIHC) and multiple immunofluorescence (mIF) are conducted to assess the association of ACOX2 expression and tertiary lymphoid structures (TLS) maturity. IC50 and clone formation assay are carried out to detected the sensitivity of PARPi to ccRCC cells with different expression level of ACOX2. Patient-derived organoids (PDOs), patient-derived xenografts (PDXs), and immunocompetent mouse models are applied to investigate the predictive value of ACOX2 to the therapeutic effect of PARPi plus anti-PD-1 antibody combination therapy in ccRCC.
Results
ACOX2 interacts with MRE11 and inhibits the binding of MRE11 and RAD50, thereby disturbing the stability of MRE11-RAD50-NBS1 (MRN) complex. Over-expressed of ACOX2 inhibits the HRR efficiency and causes the accumulation of DSBs in ccRCC cells. Furthermore, ACOX2 activates the cGAS-STING pathway and induces the formation of more mature TLS, contributing to immune-activated tumor microenvironment in ccRCC. Therapeutically, ACOX2 augments the efficacy of PARPi plus anti-PD-1 antibody combination therapy in vivo.
Conclusions
Our findings reveal a key inhibiting role of ACOX2 in HRR and suggest that the combination therapy of PARPi plus ICI could be a promising treatment strategy for ccRCC patients with elevated ACOX2 expression.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
54P - Superior antitumor activities of fourth-generation CAR-T cells containing three costimulatory domains targeting GD2-positive tumors
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
55P - Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment
Presenter: Marta Soria Castellano
Session: Poster Display session
Resources:
Abstract
56P - Potent antitumor efficiency of CD19-CAR T cells self-secreting PD-L1 x CD3 BiTE against aggressive B-cell lymphoma
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
57P - SENDER™ Directed LNP Delivery of mRNA for In Situ generation of highly potent CAR T Cells
Presenter: Biao Ma
Session: Poster Display session
Resources:
Abstract
58P - Cardiovascular outcomes of novel CAR-T cell therapies: A meta-analysis of incidence, risk factors, and management of cardiotoxicity
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract
59P - Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials
Presenter: Nicolas Mach
Session: Poster Display session
Resources:
Abstract
60P - Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
61P - Optimized protocol for the accelerated production of dendritic cell-derived exosomes (DEXs): Achieving speed without compromising efficacy
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
62P - Ecto-CRT induction of NKp46 surface expression increases osimertinib-resistant lung cancer’s sensitivity to NK cells
Presenter: Sumei Chen
Session: Poster Display session
Resources:
Abstract
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
Resources:
Abstract